Btk inhibitor 1 is primarily used in the field of medical research and therapeutic development, particularly in the treatment of B-cell malignancies and autoimmune diseases. It functions by targeting and inhibiting Bruton's tyrosine kinase (Btk), a key enzyme involved in B-cell receptor signaling. This inhibition disrupts the survival and proliferation of malignant B-cells, making it a promising candidate for conditions like chronic lymphocytic leukemia, mantle cell lymphoma, and rheumatoid arthritis. Additionally, it is being explored for its potential in addressing inflammatory disorders due to its role in modulating immune responses. Its application extends to preclinical studies, where it aids in understanding Btk signaling pathways and evaluating the efficacy of targeted therapies.